CVS HEALTH Corp
CVS HEALTH Corp (CVS) Stock News
The latest CVS headlines and market coverage — 9 recent stories, updated throughout the day.
- Zacks Investment Research·
Here's How CVS' Improving Balance Sheet Supports Deleveraging
CVS Health generated $10.6B in YTD operating cash flow and raised its full-year outlook to at least $11.5B, ending Q2 with $2.7B in cash. The company maintains a leverage ratio of 3.5x and expects improvement as it prioritizes balance-sheet strengthening over share buybacks in 2026-2027. Peers Align Technology and Cardinal Health also demonstrate strong liquidity positions with active capital deployment strategies.
- The Motley Fool·
Why CVS Stock Rallied Tuesday Morning
CVS Health stock rallied 3.4-3.7% on Tuesday following bullish commentary from Jefferies analyst Brian Tanquilut, who affirmed a buy rating with a $120 price target (28% upside). The analyst highlighted strong management guidance suggesting 2027 EPS of at least $8.44, upcoming share buybacks, and Aetna's successful turnaround with over $2 billion in year-over-year operating income growth. CVS has beaten expectations for four consecutive quarters and raised full-year guidance to $8.00 adjusted EPS (19% growth).
- Zacks Investment Research·
CVS vs. UNH: Which Health Insurance Stock Has More Upside Now?
UnitedHealth Group (UNH) emerges as the stronger investment choice compared to CVS Health (CVS), driven by improving results across UnitedHealthcare and Optum divisions, strong operating cash flows, and more attractive valuation. While CVS shows progress with Aetna margin recovery and pharmacy momentum, it faces 2027 headwinds from Caremark's 340B business challenges and expected membership decline. UNH trades at a 35% discount to its historical valuation multiple and has delivered stronger six-month returns.
- The Motley Fool·
AbbVie vs. CVS Health: Which Healthcare Stock Is a Better Buy in 2026?
The article compares AbbVie and CVS Health as healthcare investment options in 2026. AbbVie, a biopharmaceutical company with a $438B market cap, is recommended as the better choice due to its focused growth trajectory, strong drug pipeline (Skyrizi and Rinvoq), and attractive dividend yield. CVS Health, a diversified healthcare provider with a $122B market cap managing 37 million medical members, is acknowledged as a turnaround story showing stabilization but is considered less compelling than AbbVie's growth prospects.
- The Motley Fool·
1 Top Wall Street Analyst Thinks CVS Health Could Jump Another 13%. Should You Load Up on the Stock?
Mizuho analyst Ann Hynes raised her CVS Health price target to $115 per share, implying 13% upside from current levels. The article suggests CVS could see even greater upside potential, potentially reaching $150 per share if it achieves a valuation multiple similar to UnitedHealth Group, given its transformation into a diversified healthcare services company and expected double-digit earnings growth.
- The Motley Fool·
How Safe Is CVS Health's Dividend?
CVS Health's dividend is sustainable despite the company pausing annual increases. With Q1 2026 operating cash flow of $4.2 billion and expected annual cash flow of at least $9.5 billion, CVS comfortably covers its $3.39 billion projected dividend payout (representing just over 20% of cash flow). The company's 2.89% dividend yield significantly exceeds the S&P 500 average, making it an attractive income investment with minimal risk of elimination.
- GlobeNewswire Inc.·
H1 Receives $40M Investment in Round Led by CVS Health Ventures
H1, an AI-powered healthcare platform for identifying and engaging physicians, secured a $40M investment led by CVS Health Ventures. The funding follows successful collaborations between the companies, including an AI model that improved healthcare provider directory accuracy. H1 serves 85% of top 20 pharma companies and 9 out of 10 top health plans, and is on track to achieve above Rule of 40 profitability metrics in 2026.
- The Motley Fool·
CVS Health Stock Is Soaring. Could the Rally Just Be Getting Started?
CVS Health stock has surged 24% over the past month following strong Q1 earnings that beat analyst expectations, with revenue up 6.2% to $100.4B and EPS up 62% to $2.30. The company raised full-year guidance and is benefiting from improved margins in its Aetna insurance segment and growth from Rite Aid store acquisitions. However, the company carries significant debt of $86.4B in long-term obligations, though it is gradually reducing overall leverage.
- Seeking Alpha·Neutral
UnitedHealth, CVS Health tout efforts to standardize prior authorizations